Product image of Kyprolis (Carfilzomib) supplied by GNH India

Kyprolis

Active Ingredient:
Carfilzomib
Origin:
EU

Kyprolis (Carfilzomib)

Carfilzomib, the active ingredient in Kyprolis, is a proteasome inhibitor presented as a 20 mg/mL injectable solution for intravenous use. It treats multiple myeloma in patients with relapsed or refractory disease and is indicated for adult patients who have received prior therapy.

GNH India supplies Kyprolis as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The product is manufactured under EU GMP standards and distributed for clinical use.

Manufacturer / TM Owner

Amgen Europe B.V.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Kyprolis (carfilzomib) is used in the treatment of hematologic malignancies, specifically targeting proteasome activity in multiple myeloma.
  • Multiple myeloma (relapsed or refractory): improves progression‑free survival and overall response rates in patients who have received at least one prior therapy.

How It Works

  • Carfilzomib irreversibly binds to the catalytic β5 subunit of the 20S proteasome, blocking proteolytic activity. This inhibition leads to accumulation of polyubiquitinated proteins within malignant plasma cells, triggering endoplasmic reticulum stress and ultimately inducing apoptosis of the cancerous cells.

Side Effects

Common Side Effects

  • Fatigue: persistent tiredness reported by many patients.
  • Nausea: mild to moderate gastrointestinal upset.
  • Anemia: reduced red blood cell count causing weakness.
  • Thrombocytopenia: lowered platelet levels increasing bleeding risk.
  • Hypertension: elevated blood pressure during treatment.
  • Dyspnea: shortness of breath experienced by some patients.

Serious or Rare Side Effects

  • Cardiac failure: reduced heart function requiring monitoring.
  • Pulmonary embolism: blood clot in the lungs, a medical emergency.
  • Severe infusion reactions: anaphylaxis‑like symptoms during administration.
  • Tumor lysis syndrome: rapid tumor cell breakdown causing metabolic disturbances.
  • Severe dyspnea: acute respiratory distress needing immediate care.

Precautions & Warnings

Kyprolis requires careful monitoring due to its potent antineoplastic activity.

  • Cardiac monitoring: assess baseline function and watch for signs of heart failure.
  • Blood pressure control: measure regularly and manage hypertension promptly.
  • Hematologic surveillance: monitor complete blood counts for anemia, thrombocytopenia, and neutropenia.
  • Pulmonary assessment: evaluate for respiratory symptoms and intervene early.
  • Hypersensitivity avoidance: discontinue if severe infusion reaction occurs.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Kyprolis may interact with several concomitant medications.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors: may increase carfilzomib exposure and toxicity.
  • Other proteasome inhibitors: additive toxicity risk, avoid concurrent use.
  • QT‑prolonging agents: heightened risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely)

  • Anticoagulants: increased bleeding risk due to thrombocytopenia.
  • Antihypertensives: possible additive blood pressure effects.
  • CYP3A4 inducers: may reduce carfilzomib efficacy, require dose adjustment.

Frequently Asked Questions

Kyprolis, containing the active ingredient carfilzomib, is indicated for adult patients with multiple myeloma that is relapsed or refractory after at least one prior therapy. It is used to improve disease control and extend progression‑free survival in this specific patient population.

Carfilzomib works by irreversibly inhibiting the 20S proteasome’s β5 subunit, blocking protein degradation within malignant plasma cells. This leads to accumulation of polyubiquitinated proteins, causing cellular stress and triggering apoptosis of the cancerous cells.

The dosage of Kyprolis is determined by the prescribing physician based on individual patient factors such as disease status, prior treatments, and organ function. The healthcare professional will select the appropriate infusion schedule and amount for each patient.

Safety of Kyprolis in pregnancy and lactation has not been established. It should be used only if the potential benefit justifies the potential risk to the fetus, and breastfeeding is generally discouraged during treatment.

To order Kyprolis, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling) and necessary import documentation.

Kyprolis (carfilzomib) and bortezomib are both proteasome inhibitors, but carfilzomib binds irreversibly and has a distinct safety profile, often showing lower rates of peripheral neuropathy but higher incidence of cardiac events. Choice between them depends on patient tolerance, prior therapy, and physician assessment.

Kyprolis must be stored refrigerated at 2‑8 °C, protected from light, and should never be frozen or shaken. The vial should remain in its original packaging until use to maintain stability.

Kyprolis is given as an intravenous infusion by a qualified healthcare professional. The solution is diluted according to the prescribing information and infused over a defined period, typically in a clinical setting with monitoring for infusion‑related reactions.

Serious risks include cardiac toxicity such as heart failure, pulmonary embolism, severe infusion reactions, and tumor lysis syndrome. Patients should be closely monitored for symptoms like shortness of breath, chest pain, sudden swelling, or severe allergic responses.

Kyprolis should not be used in patients with known hypersensitivity to carfilzomib or any component of the formulation, and it is contraindicated in individuals with severe uncontrolled cardiac dysfunction or recent major cardiovascular events.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Carfilzomib

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT